Editas Medicine Names David Scadden, M.D., to Board of Directors
Dr. Scadden is a hematologist/oncologist and an expert on the medical applications of stem cell biology with a particular emphasis on its use in the settings of cancer and AIDS. He is the Gerald and Darlene Jordan Professor of Medicine and is Professor of Stem Cell and Regenerative Biology at
“I am very pleased to welcome David to our Board of Directors. David is an internationally recognized physician with significant experience as a physician and scientist at leading academic institutions. His work has led to several new medicines for patients with serious diseases,” said
“Editas Medicine is working at the cutting edge of science and technology, and I am honored to join its Board of Directors. I am confident that this team will bring ground-breaking medicines to patients and change the way we think of genomic diseases,” said Dr. Scadden.
Dr. Scadden holds a BA from
About
As a leading genome editing company,
Forward-Looking Statements
This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Company’s product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Quarterly Report on Form 10-Q, which is on file with the
Contacts:
Media
(617) 401-0113
cristi.barnett@editasmed.com
Investors
(617) 401-9083
mark.mullikin@editasmed.com
Source: Editas Medicine, Inc.